triazolam has been researched along with Diabetes Mellitus, Type 2 in 2 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As triazolam was administered orally to Tsumura, Suzuki, obese, diabetes (TSOD) mice and streptozotocin (STZ) mice, clearance per body (CL/F) in TSOD mice did not differ compared with Tsumura, Suzuki, non-obesity (TSNO) mice." | 1.36 | Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice. ( Ikarashi, N; Kudo, T; Ochiai, W; Ohi, K; Sugiyama, K; Toda, T; Ushiki, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kudo, T | 2 |
| Shimada, T | 1 |
| Toda, T | 2 |
| Igeta, S | 1 |
| Suzuki, W | 1 |
| Ikarashi, N | 2 |
| Ochiai, W | 2 |
| Ito, K | 1 |
| Aburada, M | 1 |
| Sugiyama, K | 2 |
| Ushiki, T | 1 |
| Ohi, K | 1 |
2 other studies available for triazolam and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity.
Topics: Animals; Cytochrome P-450 Enzyme System; Dexamethasone; Diabetes Mellitus, Type 2; Disease Models, A | 2009 |
Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice.
Topics: Animals; Blotting, Western; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitu | 2010 |